- Novartis names new head of sales U.S.
- Perrigo recalls APAP infant suspension liquid due to the possibility of missing dose markings on the dosing syringe
- Americans more likely than others to prefer generics, study finds
- Perrigo launches generic equivalent to prescription-only Vanos Cream 0.1%
- Crossmark names Janet Carter-Smith VP
ALLEGAN, Mich. Perrigo has filed for regulatory approval of a generic version of an over-the-counter medication for frequent heartburn, prompting a lawsuit from the branded version’s manufacturer.
The company announced Friday that it had filed for approval for omeprazole and sodium bicarbonate in the 20 mg/1,100 mg strength. The medication is a generic version of Zegerid OTC, made by Schering-Plough HealthCare, a subsidiary of Merck.
Schering-Plough filed a lawsuit Monday alleging patent infringement in the U.S. District Court for the District of New Jersey to prevent Perrigo’s commercialization of the product.
Zegerid had sales of around $60 million during the 12-month period ended in the “most recent month,” according to SymphonyIRI Group.